Novartis
PharmaceuticalsNot measured in this run.
Novartis scores 31.5 out of 100 on the Fameproof index, ranking 56 of 120 companies measured in the run of 5 October 2026. The index is the mean of the per-model scores below.
Visibility is uneven across models: Gemini scores it 42.0 while ChatGPT scores it 21.0, a gap of 21.0 points. A brand that is strong on one model and weak on another has a different problem from one that is mid-table everywhere.
Gemini names Novartis in 38% of answers and places it early enough to score 15% on prominence; ChatGPT names it in 10%.
Across the 24-prompt panel there are 4 prompts where at least one model does not name Novartis at all — those are the answers a competitor is winning instead, and the table below shows which.
Measured inside pharmaceuticals rather than the wide healthcare pool, Novartis scores 70.5 — the fairer question for a buyer already shopping that market, though it cannot be compared across markets.
Prompt performance
Position when mentionedHead to head
Who the models name more often, side by side.
Is this you?
Get the full audit: every losing prompt, the exact answers, and the source changes that move the index.
Request an audit — $299Ranked either side
Healthcare, nearest on the index.
See all healthcare and pharmaceutical companies →Questions about this score
What is Novartis's AI visibility score?
Novartis scores 31.5 out of 100 on the Fameproof index, ranked 56 of 120 companies, measured on 5 October 2026 across ChatGPT and Gemini.
Which AI model mentions Novartis most?
Gemini, at 42.0 out of 100, naming Novartis in 38% of the answers in its panel. The per-model breakdown is above.
How is Novartis's score measured?
With a panel of 24 category questions asked 4 times per model — never questions that name Novartis, because a prompt that names you guarantees a mention. The score combines how often it is named, how early in the answer, how much of the topic it covers, and how consistent the result is between repetitions. Full methodology.